Consequently, the inactivation of KLRB1 or antibody‐mediated blockade of CD161 restores T cell metabolic capacity, thereby enhancing cytotoxicity against tumor cells and augmenting systemic antitumor immune responses [45]. This evidence concerns the gene KLRB1 and neoplasm.